Abstract
The estrogen receptor (ER) status in primary breast cancer represents an important prognostic factor and has a profound impact on therapeutic decisions. However, ER expression profile on disseminated breast cancer cells is largely unknown, although these cells are one of the main target structures in adjuvant therapy after local curative resection (R0) achieved in most breast cancer patients. Thus, the present pilot study was designed to evaluate the ER expression profile on disseminated epithelial cells in bone marrow, one of the preferential organs for manifestation of distant metastases in breast cancer. Using the alkaline phosphatase anti-alkaline phosphatase-immunogold double staining procedure, in a panel of 17 breast cancer patients, epithelial cells (mab CK2) detected in bone marrow were analyzed for ER expression (mab 1D5) and compared with ER expression in the corresponding primary tumors. Whereas eleven of the 17 patients (64.7%) were ER-positive in primary carcinomas, only two patients (11.8%) revealed ER-positive epithelial cells in bone marrow. In addition, one of these two patients demonstrated a heterogeneous ER expression pattern, with both ER-positive and ER-negative epithelial cells in bone marrow. Although in both of these cases the ER-positive epithelial cells in bone marrow derived from ER-positive primary tumors, in this small patient cohort none of the prognostic relevant clinical and pathological factors tested, i.e., TNM-classification, grading, and ER status in primary breast cancer, correlated with the ER status in bone marrow. The striking discrepancy between ER expression in primary breast cancers and the corresponding disseminated epithelial cells in bone marrow suggests either the selective dissemination of ER-negative tumor cells into the bone marrow or a negative impact of the bone marrow microenvironment on epithelial ER expression. This phenomenon might influence therapeutic effects of antihormonal treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ER-alpha and ER-beta at API sites. Science 277:1508–1510
Key TJ, Wang DY, Brown JB, Hermon C, Allen DS, Moore JW, Billbrook RD, Fentiman IS, Pike MC (1996) A prospective study of urinary estrogen excretion and breast cancer risk. Br J Cancer 73 12:1615–1619
McPherson LA, Baichwal VR, Weigel RJ (1997) Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA 94:4342–4347
Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 16:557–566
Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfi T, Kindermann G, Riethmüller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533
Funke I, Schraut W, Untch M, Schlimok G, Jauch KW, Schildberg FW (2001) Prognoserelevanz disseminierter Tumorzellen im Knochenmark: Prospektive Studie an 1045 Mammakarzinom-Patientinnen im Stadium I–III. Langenbecks Arch Surg 30:547–5497
UICC (1997) TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York
Zia A, Schildberg FW, Funke I (2001) MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 93:566–570
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
Andersen J, Orntoft T, Skovgaard Poulsen H (1986) Semiquantitative estrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer 53:691–694
Wasserman L, Dreilinger A, Easter D, Wallace A (1999) A seminested RT-PCR assay for Her-2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn 4:21–28
Gebhardt F, Zanker KS, Brandt B (1998) Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients. Biochem Biophys Res Commun 247:319–323
Braun S, Pantel K (1998) Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 52:201–216
Hazan RB, Norton L (1998) The epidermal growth factor receptor modulates the interaction of the E-cadherin with the actin cytoskeleton. J Biol Chem 273:9078–9084
Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmüller G (1991) Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51:4712–4715
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ditsch, N., Mayer, B., Rolle, M., Untch, M., Schildberg, F.W., Funke, I. (2003). Estrogen Receptor Expression Profile of Disseminated Epithelial Tumor Cells in Bone Marrow of Breast Cancer Patients. In: Allgayer, H., Heiss, M.M., Schildberg, F.W. (eds) Molecular Staging of Cancer. Recent Results in Cancer Research, vol 162. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59349-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-59349-9_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63945-6
Online ISBN: 978-3-642-59349-9
eBook Packages: Springer Book Archive